Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2018, Article ID 4019248, 6 pages
https://doi.org/10.1155/2018/4019248
Clinical Study

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance

1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Correspondence should be addressed to Xinyu Shao; moc.361@2oahsyx and Bimin Shi; moc.361@nimibihs

Received 29 July 2017; Accepted 22 November 2017; Published 6 February 2018

Academic Editor: Hiroshi Okamoto

Copyright © 2018 Xuan Du et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. J. Kim, H.-Y. Shin, Y. Chang et al., “Metabolically healthy obesity and the risk for subclinical atherosclerosis,” Atherosclerosis, vol. 262, pp. 191–197, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. Liu, F. Ma, H. P. Lou, and Y. Chen, “Visceral adiposity index is associated with pre-diabetes and type 2 diabetes mellitus in Chinese adults aged 20-50,” Annals of Nutrition & Metabolism, vol. 68, no. 4, pp. 235–243, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Schlecht, W. Gronwald, G. Behrens et al., “Visceral adipose tissue but not subcutaneous adipose tissue is associated with urine and serum metabolites,” PLoS One, vol. 12, no. 4, article e0175133, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. S. L. Dickson, R. H. Shirazi, C. Hansson, F. Bergquist, H. Nissbrandt, and K. P. Skibicka, “The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors,” Journal of Neuroscience, vol. 32, no. 14, pp. 4812–4820, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Sönmez, M. Dinç, A. Taşlıpınar et al., “Add on exenatide treatment is beneficial in poorly controlled obese type 2 diabetics under intensive insulin regimens,” Experimental and Clinical Endocrinology & Diabetes, vol. 125, no. 4, pp. 256–261, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Morano, E. Romagnoli, T. Filardi et al., “Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study,” Acta Diabetologica, vol. 52, no. 4, pp. 727–732, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Yoshizumi, T. Nakamura, M. Yamane et al., “Abdominal fat: standardized technique for measurement at CT,” Radiology, vol. 211, no. 1, pp. 283–286, 1999. View at Publisher · View at Google Scholar
  8. S. Ghosal, B. Sinha, and K. K. Gangopadhyay, “Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: a retrospective real world comparative data from India,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 10, no. 3, pp. 161–165, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Sakamaki, Y. Maejima, Y. Tokita et al., “Impact of the visceral fat area measured by dual impedance method on the diagnostic components of metabolic diseases in a middle-aged Japanese population,” Internal Medicine, vol. 55, no. 13, pp. 1691–1696, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Hershkop, O. Besor, N. Santoro, B. Pierpont, S. Caprio, and R. Weiss, “Adipose insulin resistance in obese adolescents across the spectrum of glucose tolerance,” The Journal of Clinical Endocrinology & Metabolism, vol. 101, no. 6, pp. 2423–2431, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Taylor, “Good fat, bad fat–does location matter?” Radiology, vol. 242, no. 3, pp. 645-646, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Gastaldelli, M. Gaggini, G. Daniele et al., “Exenatide improves both hepatic and adipose tissue insulin resistance: a dynamic positron emission tomography study,” Hepatology, vol. 64, no. 6, pp. 2028–2037, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Inoue, N. Maeda, S. Kashine et al., “Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes,” Cardiovascular Diabetology, vol. 10, no. 1, p. 109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. D. H. van Raalte, M. C. Bunck, M. M. Smits et al., “Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial,” European Journal of Endocrinology, vol. 175, no. 4, pp. 345–352, 2016. View at Publisher · View at Google Scholar · View at Scopus